| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = -$148,749 ) |
| | 2024 | 2020 | BIOCOGNIV INC | 50 LAKESIDE AVE., SUITE 851 | BURLINGTON | VT | 05401-6029 | CHITTENDEN | USA | R43HL154941 | Development of a Novel Diagnostic Test for Pulmonary Embolism Based on Artificial Intelligence and Spectral Analysis of Blood | 000 | 1 | NIH | 10/12/2023 | -$148,749 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2020 | BIOCOGNIV INC. | 50 LAKESIDE AVE STE 851 | BURLINGTON | VT | 05401-5242 | CHITTENDEN | USA | R43HL154941 | Development of a Novel Diagnostic Test for Pulmonary Embolism Based on Artificial Intelligence and Spectral Analysis of Blood | 000 | 1 | NIH | 11/18/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $299,749 ) |
| | 2020 | 2020 | BIOCOGNIV INC. | 4 OAK HILL DR | SOUTH BURLINGTON | VT | 05403-7344 | CHITTENDEN | USA | R43HL154941 | Development of a Novel Diagnostic Test for Pulmonary Embolism Based on Artificial Intelligence and Spectral Analysis of Blood | 000 | 1 | NIH | 8/24/2020 | $299,749 |
|
|
